UK-based MiNA Therapeutics has started the Phase I clinical trial (TIMEPOINT) of MTL-CEBPA for the treatment of patients suffering with advanced solid tumours.
TIMEPOINT is a global Phase I/Ib clinical trial is designed to assess the safety and tolerability of MTL-CEBPA, an saRNA restoring the expression of C/EBP-a, in patients with advanced solid tumour.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The clinical study is being conducted in combination with anti-PD1 checkpoint inhibitor pembrolizumab in these patients.
The MTL-CEBPA is composed of a double-stranded RNA formulated into a SMARTICLES liposomal nanoparticle, and is intended to activate the CEBPA gene, which encodes the CCAAT / enhancer binding protein alpha (C/EBP-a).
MiNA Therapeutics noted that the drug is also being investigated in an ongoing multi-centre Phase Ib study in patients suffering with advanced liver cancer and is being conducted in combination with sorafenib.
MiNA Therapeutics CEO Robert Habib said: “Initiation of the Phase I TIMEPOINT clinical trial emphasises the continued exploration of MTL-CEBPA, the first drug candidate that targets C/EBP-α, a master regulator of immune cells that play a critical role in tumour resistance.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are excited to take the next step and test MTL‑CEBPA in additional cancer populations in a potentially synergistic combination with an anti-PD1 checkpoint inhibitor.”
According to the company, the TIMEPOINT trial comprises a dose-escalation followed by a dose expansion.
MTL‑CEBPA will be administered as an intravenous infusion once a week for three weeks, followed by one week of rest between each cycle.
The pre-clinical studies of the drug candidate have demonstrated that the anti-tumour activity of anti-PD1 checkpoint inhibition has been shown to reduce immune suppression from dysregulated myeloid cells.
